在实践中OAB的临床特征和当前药物治疗:理想和现实
Kazuna Tsubouchi1, Hisatomi Arima2, Taiki Emoto1
1Department of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Advances in therapy
|December 24, 2024
概括
过度活性膀 (OAB) 治疗通常以β3-上腺激动剂 (β3A) 开始,与抗胆固醇药 (anti-AChR) 相比,不良事件没有显著差异. 医生意识是改善OAB患者生活质量的关键.
科学领域:
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 医疗保健服务研究 医疗服务研究
背景情况:
- 过度活性膀 (OAB) 药物治疗通常涉及抗胆固醇药物 (anti-AChR) 和β3-上腺激动剂 (β3A).
- 了解处方模式和不良事件 (AE) 概况对于优化OAB管理至关重要.
- 大规模的数据分析可以揭示现实世界的治疗趋势和结果.
研究的目的:
- 研究OAB药物治疗中抗AChR和β3A的处方模式.
- 为了比较抗AChR和β3A之间的不良事件 (AE) 的频率.
- 分析治疗变化,并确定影响OAB管理的因素.
主要方法:
- 使用JMDC索赔数据库从2015年5月到2023年4月进行的回顾性队列研究.
- 对抗AChR和β3A使用者的患者特征,处方模式和AE发病率的分析.
- 多变量分析以评估初始药物处方和AE风险之间的关联.
主要成果:
- 分析了70,936名患者;OAB治疗经常以β3A开始,特别是在男性中,主要是在临床环境中.
- 治疗变化 (药物类别转换或附加疗法) 发生在约10%的患者中,β3A的变化率更高.
- 抗AChR与β3A的初始处方没有显示出与不良事件风险的显著关联.
结论:
- β3A经常是OAB药物治疗的首选,主要在门诊处方.
- 治疗修改率低表明需要提高医生意识,以提高OAB患者的生活质量.
- 该研究发现,基于最初的药物类别,AE发病率没有差异,这凸显了对特定AE风险的进一步研究的需要.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
01:21Drugs for Treatment of Constipation-Predominant IBS
133
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
133
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
139
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
139
01:28Drug Therapy
38
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
38
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
166
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
166
01:26Psychosis: Goals of Pharmacotherapy
103
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
103